Anemia Pharm Flashcards

1
Q

treatment of iron deficiency anemia

A

-ferrous sulfate (oral)
-iron dextran (parenteral)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ferrous sulfate and iron dextran indications

A

-treat and prevent iron deficiency anemia
-treat blood loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ferrous sulfate and iron dextran interactions

A

-decrease absorption with antacids
-increased absorption with vitamin C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ferrous sulfate and iron dextran adverse effects

A

-GI- nausea, heartburn, constipation
-metallic taste
-staining of teeth (oral)
-fatal iron toxicity (OD in children causing liver failure)
-leading cause of poisoning death in children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

chelating agent

A

deferoxamine/desferal: drug given to treat iron toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

administration of oral iron

A

-best absorbed on empty stomach
-taking with food however decreases the gastric irritation many people have with oral iron
-do not give with antacids or calcium
-do not crush or chew
-liquid form: give with a straw and diluted in OJ to increase absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

parenteral iron administration

A

-give test dose
-black box warning: have epi available for possible allergic reaction
-IM form- use 1.5 inch needle with z-track method to prevent skin staining

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

treatment of B12 deficiency

A

-injections of cyanocobalamin
-diet: meat, salmon and cod, milk and other dairy products, eggs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

treatment of folate deficiency

A

-diet: increase consumption of leafy greens, legumes and organ meats
-multivitamin
-OTC folic acid supplements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

cyanocobalamin indications

A

-low B12 levels- pernicious anemia; bariatric patients need 1 mg B12 daily indefinitely; surgeries where all parts of the stomach are removed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

cyanocobalamin

A

-diet: increase meat, fish, eggs, milk
-oral- 1-2 mg daily
-injectable: IM weekly until levels are near normal, then monthly
-tolerated well- may have redness or pain at injection site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

folic acid supplement indications

A

to treat folic acid deficiency anemia, in pregnant women to prevent neural tube defects
-diet: increase fortified grains, fresh fruits and veggies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

erythropoiesis stimulating agent

A

epoetin alfa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

epoetin alfa MOA

A

stimulates erythropoiesis; increases hgb and reticulocyte counts: only indicated when hgb is less than 10 g/dL UNLESS on dialysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

epoetin alfa route

A

IV and Subq

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

erythropoietin stimulating agents indication

A

treatment of anemia due to CKD, HIV patient on the drug zidovudine, people on chemo, autoimmune hemolytic anemia

17
Q

erythropoietin stimulating agents monitoring

A

-blood tests weekly to monitor hgb with goal of less than 11 g/dL to decrease risk for clotting
-evaluate iron status before and during treatment-usually need iron supplementation

18
Q

erythropoietin stimulating agents side effects

A

-HTN and serious CV events
-progression of certain cancers
-injection site problems, bone pain, headache

19
Q

erythropoietin stimulating agents Nursing Implications

A

-do not give epogen that has been shaken or frozen
-protect from light
-do not dilute or mix with other drugs
-epogen is contraindicated in patients with uncontrolled HTN
-levels of Hgb typically begins to rise in about 2 weeks
-black box warning: in controlled trials patients experienced greater risks for death, serious adverse CV reactions, and stroke when administered ESAs to a target hemoglobin >11 g/dL